Already a member?
Login
Become a member
Register
Home
About
About PCSK9 Forum
Editorial Board
Mission Statement
About PCSK9
What are PCSK9 inhibitors?
Why are new treatments needed?
Which patients may benefit?
News
News
Meeting Reports
Expert Meetings
Commentary
Hot topics
From the Editors
Questions of the Month
Slides
Slide resource programme
Slides by Editorial Board
Trials
Videos
Resources
Trials
Slides by Editorial Board
Events
Videos
Webcasts
Guidelines & Consensus Guidance
Article Archive
Contact
⇒ Main Menu
Home
About
– About PCSK9 Forum
– Editorial Board
– Mission Statement
– What are PCSK9 inhibitors?
– Why are new treatments needed?
– Which patients may benefit?
News
– News
– Meeting Reports
– Expert Meetings
– Hot topics
– From the Editors
– Questions of the Month
Slides
– Slide resource programme
– Slides by Editorial Board
Trials
Videos
Resources
– Trials
– Slides by Editorial Board
– Events
– Videos
– Webcasts
– Guidelines & Consensus Guidance
– Article Archive
Contact
News
Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia
YELLOW III supports aggressive lipid lowering to reduce plaque progression
CLEAR Outcomes shows 13% reduction in CV events with bempedoic acid
Olpasiran reduces Lp(a) irrespective of baseline Lp(a)
AT-TARGET-IT: Real world data show high adherence to PCSK9 inhibitors
Genetic variants in PCSK9 gene not linked to heart failure
Latest News Updates
Profile